Flaws in New Cancer Drug Trial | Ivosidenib & Aza vs Aza | AGILE | NEJM | Plenary Session | Timeline
Вставка
- Опубліковано 8 лют 2025
- Vinay Prasad, MD MPH; Physician & Associate Professor
Google Scholar: scholar.google...
Substack: vinayprasadmdm...
Podcast: podcasts.apple...
Personal Website: www.vinayakkprasad.com
Laboratory Website: www.vkprasadlab.com
Podcast Website: www.plenarysessionpodcast.com
Academic Publications: www.vinayakkpra...
Follow me on:
Twitter @vprasadmdmph
Now this is the Dr Prasad not everyone gets to see. I like this message of concise outrage against the presiding paradigm. 💪👍
It has been allowed as you are railing against. So much of the medical industry (and it is an industry) is complicit, not just oncology. Thank you for putting these out!
You sir, are a national treasure
Agree completely!
I love the way you are able to critique studies! We need more people like you in positions that can make change happen.
Lots of people see these problems. Most work at institutions at which they fear losing their jobs if they speak up. You have to have nothing to lose, or be positioned where you have support, which is increasingly harder to find.
They need to just think of mankind.
@@2hotscottpro if only!
Thank you as always.
Thank you. Someday, they will reap what they are sowing. It is wonderful that you are standing up for the actual patients.
Stunning analysis. Thank you.
Thanks for fighting the good fight Vinay. I hope you are well
This is great, more doctors need to read the studies themselves!
Thank you for bringing this to light to the common person. You are a blessing to us all!
I don't know what most of this means, but I love when VP gets fired up!
It means this study/ medicine is shit
Thanks Vinay! I love your videos calling out corrupt public health. This one was a bit technical for me, but still got the main ideas.
You are awesome and I applaud what you do. I wish more were as courageous as you to come against injustices that others don’t have the knowledge or know how to address. Thank you for your time and expertise and wanting to do the right thing. Blessings to you.
Thank you, Prof Prasad, to bring us to the battlefield!
Vinay please interview david healy and peter doshi
I know two cancer survivors, thank you for helping keep the data trials for new treatments honest.
The cat is out of the bag with medical and pharma
thank you again Dr.Vinay Prasad!
This man is a doctor. Thank you. We wish all doctors were like you. They’ve become like sleazy ambulance chasing lawyers.
Thank you for presenting this. But, discouraging information
*has to be called out. a regulator would be nice.* accelerated approval leading to negligent controls to push even more drugs to market w substandard research; changing end points (why we pre-register. along w stopping halt.); oh, & early halt; & (industry) medical writer.
they were trying to just round it up as quick as possible. & take a win. trials are hard, fine. but once this far in, w this level of money on the table: just do it right. it's not *that* much harder (...& is the career chosen). gr8 entry. -JC
I analyze drug trial data for a living but not from a purely statistical perspective. So it's interesting to me to hear this aspect being analyzed since it is largely irrelevant to my models.
I listened to the Oncology Drugs Advisory Committee at the Food and Drug Administration's yt site 7 hrs ago.
And others as well regarding children's cancer.
One thing I find missing is the WHY all of this is happening ...the intent being only in these treatments that sounded so drastic and excruciating .... Difficult to tolerate.
We have to eliminate cancer causes and WE KNOW PLENTY.
CHILDREN WITH "RARE" CANCERS and people WITH all manner of things.
Thank you Dr Prasad for this informative video, I was just at the AML Academy in the UK and this article about the AGILE trial was presented as a potential practice changing trial outcome, though the criticism of it was also mentioned.
Can I just ask you in which trial is found that ven/aza is possibly more beneficial in IDH (IDH1) mutant AML patients please? Is it just the VIALE trial? Thank you.
Hi, Vinay - it would be great if you had the link to the journal that the article was published in, in the video description.Thank you for explaining these hairy research studies.
Yeah this isn't a revelation.Any one with passing familiarity of AML treatment knows this study is already out of date with the Aza comparitor arm. I think all the adjustments were attempts to salvage something. After Aza/Ven press release came out (mind you not the publication that was very delayed) it would be unethical to accrue to the original planned number. They had to downgrade to EFS with the lower number. Even after that they took the first opportunity to stop the study.Also for patients on Aza only the natural pick for the second line probably was Aza/Ven and not Aza/Ivosesinib.
Dr.Prasad needs to analyze in good faith. The guys who ran the trial were academics just like him making the best of a bad situation .I mean I can't think of what we're supposed to do. They were seeing positive data and Vialy A data would take another year and a half to be made public. Does it deserve getting published in NEJM? I think it does because so little has ever moved the needle in AML.Randomise phase III trials are a rarity.Would you want the trend of retrospective and underpowered phase 2 to continue instead?
Doing trials for a deadly disease such as AML will always be a challenge but there is no other way to improve outcomes. We have done 30 yrs of 7+3 with miserable results. We shouldn't posien the well when we finally have agents that everyone agrees deserve to be investigated.
It seems to me that if something deserves to be investigated, that means the trial is still ongoing. On the other hand, advocating for a treatment that's under investigation to become the standard of treatment is irresponsible.
My mom has cholangiocarcinoma... is taking Tibsovo fo the 2nd day. She is very tired and weak. God help her!
I don't know anything about these types of studies or anything. But the information that we have something that helps prevent death is acknowledged during the study and they continue to not give that patient that helpful drug sounds criminal. If they weren't on the study they would be given that treatment and possibly have had a higher standard of living before passing away or just not passing away entirely.
This just seems completely unethical to me and sounds like it would go against the Hippocratic oath. I completely understand and feel that Dr. Prasad's anger and frustration about this study is 100% warranted. I am also disgusted by these facts, if they are in fact as Dr. Prasad claims (and Dr. Prasad has only given me many reasons to trust him as a reliable source and never any reason to doubt his opinions and analysis.)
If this were children with cancer- they’d be sued big-time. I know, I had a child with leukemia. Fortunately, she revcivef in treatment -thanks to CCG and their standard of care even in “experimental treatment” protocols.
5:53 not sure of what you said ?
Where’s the vaunted “peer review”? And who where they? Negligence at NEJM?
Poor drug trials is turning into a trend
This is how you read a paper.
Dr Prasad's thumbnail alone broke my Cynicism-meter... out-of-range... and I haven't even started...
My money's on follow the perverse incentives.
I wonder if he has a picture of somebody that he really does not like in front of him so it's easier than just talking into a camera.
Kind of off topic.. but I have a daughter, 21 years old at diagnosis of ALL. Wbc at diagnosis was 8k, ph (-), pre B ALL. No adverse cytogenetics. At diagnosis her hemonc recommended hyper CVAD, followed by consolidation with allogenic HSCT. Well, I didn’t agree with that recommendation, all the research and data I saw supporting a pediatric inspired regimen such as Augmented BFM. I found another oncologist at a different institution that went with the pediatric regimen even though she was 21. She’s now done with 42 weeks of intense inpatient chemo, which included induction, (MRD - after 4 weeks) reinduction, consolidation, interim maintenance x 2,and reintensification x 2. And is now in week 48 of maintenance. Has been in remission for almost 2 years. My question is why there aren’t recent clinical trials comparing pediatric regimens head to head with hyper CVAD/ adult regimens that randomized for the adolescent age group so we can get a definitive answer to which is better and have one standard of care for this age group not different regimens that depend on institutions comfort level
Good luck to both of you. Well done sir.
@@ms-jl6dl thank you for your kind wishes :) just trying to stick with the best available evidence based medical management for her… but evidence and data for her age group is lacking… idk why there are so few trials that focus on adolescent and young adults in leukemia…
Clap, clap, clap, clap, clap!! WTF!!!! How can we stop this sort of thing and hold the bubble-gum reviewers accountable?
Dr. Prasad, have you considered that you are just miles ahead of the medical community? Sad but the level of overall intelligence seems to have been negatively impacted by the way the industry is run. Docs not writing their own papers .... what does that say?
Nope. These people are smart. One cant get that 6 figure consulting gig if they reject the trial.
Why does NEJM keep publishing this tripe? There might have been something interesting this trial could have told us, but they monkeyed around with the end points without considering recents trends in treatment. It’s such a waste.
I think volume was a smidge low. Great content.
I think he needs more treble.
@@mballer you misspelled "🐄 bell"
So,is this murder?
Vinay it’s late. Get rest and focus on how your going to help us defeat this Covid vaccine mandate for healthcare workers. This vaccine has failed more than any cancer drug you analyze
AZT?
You have forgotten that he is a cancer doctor. Not everything is covid. Also cancer is very serious
@@bleelac cancer is indeed serious. His other focus or specialty is epidemiology and he is expert and reviewing data/research. I’m compelling him to do honest assessment of limitations of “vaccine”. We need our top physicians to stop allowing politics and fear from giving true assessments. Bunch of zombies or sheep.